Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bioenvision Charts. Click Here for more Bioenvision Charts.](/p.php?pid=staticchart&s=N%5EBIVN&p=8&t=15)
Bioenvision, Inc. (NASDAQ:BIVN) Bioenvision today
announced its abstract on Suvus(TM) has been accepted for the British
Association for the Study of the Liver's 2006 Annual Meeting in
Dublin. The meeting on September 7-8th at Trinity College provides
Bioenvision the first opportunity to present data from a Phase II
study of Suvus(TM) in chronic hepatitis C and refractory hepatitis C.
"We are excited to be sharing our promising results with hundreds
of doctors and nurses at this prestigious international meeting," said
Dr. Christopher Wood, Chairman and Chief Executive Officer of
Bioenvision. "Hepatitis C has been compared to a 'viral time bomb' and
we are excited that Suvus(TM) may be a potential treatment option for
millions of people infected around the world."
Suvus(TM) showed clear evidence of activity and significantly
reduced the viral load in chronic hepatitis C patients, many who have
cirrhosis of the liver. The study was done in Egypt, a country with
one of the highest prevalence rates of hepatitis C in the world with
an estimated 7-8 million Egyptians infected with hepatitis C.
"The data from this Phase II study forms the basis for our
regulatory filing in Egypt," said David Luci, Bioenvision's General
Counsel and Chief Financial Officer. "We have initiated the filing
process and are in discussions with Egyptian regulatory authorities."
Besides Suvus(TM) showing efficacy in hepatitis C, studies have
also shown Suvus(TM) offers an indication of activity in the West Nile
Virus and flu strain H5N1, otherwise known as the "avian flu." "We
plan to initiate further clinical and preclinical trials of Suvus(TM)
on the basis of this encouraging data," said Hugh Griffith,
Bioenvision's Chief Operating Officer.
About Bioenvision
Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra(R), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies, including
the OLIGON(R) technology; an advanced biomaterial that has been
incorporated into various FDA approved medical devices and Suvus(TM),
an antimicrobial agent currently in clinical development for
refractory chronic hepatitis C infection. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.